23
Jun

Compliance With Clinical Trials Posting – Understanding the Requirements

Over the last six to eight months, the FDA’s activity regarding compliance with the required posting of ongoing and completed clinical trials has significantly increased, as evidenced by the issuance of multiple warning letters and letters of non-compliance to sponsors and/or principal investigators. To assist responsible parties in complying with the requirement to post on […]

Read More
17
Jun

Modification to iPLEDGE Program Implementation Delayed to November 2026

Yesterday, the FDA announced that the modification made to the iPLEDGE Program Risk Evaluation and Mitigation Strategy (REMS), previously announced in November 2023 and approved on March 8, 2026, has been pushed back until November 15, 2026 “to allow additional time to test iPLEDGE REMS system updates, minimize technical issues for users of the iPLEDGE REMS platform, […]

Read More
12
Jun
Patent Listings by NDA Sponsors: The Who, What, Why, Where, and How Q&A Document

Patent Listings by NDA Sponsors: The Who, What, Why, Where, and How Q&A Document

Today, the FDA published a draft guidance titled Forms FDA 3542a and FDA 3542: Questions and Answers (here) that provides NDA sponsors with more information on patent submission than perhaps you ever even thought possible.  The document identifies twenty-nine different questions and corresponding answers to clarify who needs to submit patent information, what patent information […]

Read More
03
Jun
If a Product Is Found to Be Safe, Should We Just Forget About Efficacy? Not On My Watch!

If a Product Is Found to Be Safe, Should We Just Forget About Efficacy? Not On My Watch!

On June 2, 2026 in The Wall Street Journal, Charles L. Hooper and David R. Henderson wrote “…Remove efficacy from the FDA’s approval process and focus on safety alone.  That would improve doctors’ ability to match patients with the best drugs and help Americans live longer, healthier lives.  Medicine is a matchmaking exercise in which potentially beneficial drugs […]

Read More
29
May

FDA Issues Draft Guidance Aimed at Reducing Non-Clinical Animal Studies

Today, the FDA published a draft guidance titled “Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products: Guidance for Industry,” aimed at implementing streamlined approaches for nonclinical safety assessments of certain oncology pharmaceuticals. The draft guidance can be found here. The document provides some interesting background on the evolution of the Agency’s thinking […]

Read More
27
May

An Interesting Issue That May Impact FDA and Industry

A Federal Register (FR) notice that appeared on today’s pre-publication page discusses a request for comments on a draft nondisclosure agreement (NDA) for federal employees. The notice (here) discusses the proposed NDA to affirm “[f]ederal employees’ acknowledgment of, and agreement to comply with, current legal obligations to safeguard non-public, confidential, or proprietary information, created or […]

Read More
26
May
FDA Finalizes DESI Notice on Estrogen-Androgen

After 50+ Years, FDA Finalizes DESI Notice on Estrogen-Androgen Fixed Combination Drug Products

The Federal Register (FR) notice (here) appearing on today’s pre-publication page describes the long and tedious process of finalizing one of the last remaining Drug Efficacy Study Implementation (DESI) notices, and ends with a final FDA decision that there is a lack of substantial evidence of efficacy for the use of certain estrogen-androgen fixed combination […]

Read More
04
May

Get Ready for PDUFA Program Fee Invoices for 2027

Today, the FDA sent out a PDUFA Dear Colleague letter (here) asking firms to verify program fee assessment information that the Agency has relative to applications covered under PDUFA VII.  The letter states that “[u]nder PDUFA VII, a program fee is assessed annually for certain prescription drug products identified in a human drug application approved as of […]

Read More
29
Apr

FDA Proposes to Withdraw Approval of Tavneos NDA After New Information Comes to Light

On April 29, 2026, the FDA published a notice in the Federal Register (FR) (posted on the FR prepublication page (here)) announcing the FDA’s intention to withdraw approval of the New Drug Application (NDA) for TAVNEOS (avacopan) capsule, 10 milligrams (mg), held by ChemoCentryx, Inc. and offer the applicant an Opportunity for a Hearing regarding the FDA’s […]

Read More
1 2 3 4 … 35